Home » Stocks » Hoth Therapeutics

Hoth Therapeutics, Inc. (HOTH)

Stock Price: $1.77 USD -0.03 (-1.67%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 23.78M
Revenue (ttm) n/a
Net Income (ttm) -9.93M
Shares Out 13.43M
EPS (ttm) -0.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $1.77
Previous Close $1.80
Change ($) -0.03
Change (%) -1.67%
Day's Open 1.84
Day's Range 1.75 - 1.84
Day's Volume 107,597
52-Week Range 1.73 - 7.25

More Stats

Market Cap 23.78M
Enterprise Value 16.82M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 13.43M
Float 8.77M
EPS (basic) -0.96
EPS (diluted) -0.93
FCF / Share -0.58
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 27,692
Short Ratio 0.10
Short % of Float 0.32%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.52
Revenue n/a
Operating Income -9.12M
Net Income -9.93M
Free Cash Flow -7.12M
Net Cash 6.96M
Net Cash / Share 0.52
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -104.93%
ROE -180.18%
ROIC -1,046.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $1.77
Target: 10.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-7.71-2.50
Net Income-7.70-2.50
Shares Outstanding9.165.03
Earnings Per Share-0.84-0.50
Operating Cash Flow-4.95-2.10
Free Cash Flow-4.95-2.10
Cash & Equivalents2.690.28
Net Cash / Debt2.690.28
Book Value2.400.15
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Hoth Therapeutics, Inc.
Country United States
Employees 2
CEO Robbie Knie

Stock Information

Ticker Symbol HOTH
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: HOTH
IPO Date February 15, 2019


Hoth Therapeutics, a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. It intends to use the BioLexa Platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company has license agreements with the George Washington University; the University of Maryland Baltimore; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Zylö Therapeutics, Inc.; Chelexa BioSciences, Inc.; and the University of Cincinnati. Hoth Therapeutics, Inc. was founded in 2017 and is headquartered in New York, New York.